-
2025-522232-13-00
4
2026-03-06
Sepsis-associated acute kidney injury (AKI)
-
2025-521284-12-00
5
2026-03-05
Non-small cell lung cancer
-
2025-523347-35-00
11
2026-03-05
Atopic Dermatitis
-
2025-521035-37-00
5
2026-03-02
Immune system diseases
-
2025-522015-42-00
10
2026-02-26
Chronic Hepatitis D Infection
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2024-511362-37-00
5
2026-02-18
Non squamous non-small cell lung cancer (NSCLC)
-
2024-516356-18-00
5
2026-02-17
Atherosclerotic cardiovascular disease (ASCVD)
-
2025-523412-36-00
3
2026-02-17
Systemic lupus erythematosus, Rheumatoid arthritis
-
2025-521873-15-00
9
2026-02-09
Metastatic hormone-sensitive prostate cancer
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2025-521043-20-00
10
2026-01-27
Neuroendocrine tumors
-
2025-522333-61-00
4
2026-01-23
Hidradenitis suppurativa
-
2024-515023-11-00
5
2026-01-22
Metastatic Clear Cell Renal Cell Carcinoma
-
2025-521917-24-00
5
2026-01-21
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
-
2025-521441-24-00
7
2026-01-19
Advanced or Metastatic Solid Tumors
-
2024-519798-20-00
4
2026-01-15
pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)
-
2025-522862-58-00
5
2026-01-09
Locally advanced unresectable or metastatic gastric or gastroesophagea
-
2024-517653-27-00
4
2025-12-17
Prostate Cancer
-
2025-523009-14-00
4
2025-12-16
Bronchiectasis with chronic pseudomonas aeruginosa colonization
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2024-519712-13-00
5
2025-12-08
Hypertriglyceridemia (HTG)
-
2025-520730-28-00
4
2025-12-08
Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung